BioCentury
ARTICLE | Regulation

Crystalizing a Place for Krystexxa

June 22, 2009 7:00 AM UTC

Assuming FDA concurs with last week's positive advisory panel vote for Krystexxa pegloticase to treat refractory chronic gout, the next big task for Savient Pharmaceuticals Inc. is likely to be positioning Krystexxa in a market in flux.

FDA's Arthritis Advisory Committee voted 14-1 to recommend approval of Krystexxa after concluding the benefits of the pegylated urate oxidase trumped concerns about safety...